GeneOne Life Science Inc., which partnered with Inovio Pharmaceuticals Inc (NASDAQ:INO) to develop Inovio’s MERS vaccine (GLS-5300), announced the filing of an Investigational New …
Maxim analyst Jason McCarthy came out with a brief commentary on Inovio Pharmaceuticals Inc (NASDAQ:INO), after the company announced yesterday that the US Defense Advanced Research Projects Agency (DARPA) has …
Inovio Pharmaceuticals Inc (NASDAQ:INO) announced that the U.S.
Inovio Pharmaceuticals Inc (NASDAQ:INO) announced that The Lancet, one of the world’s leading medical journals, published a peer-reviewed article detailing the successful results of …
Inovio Pharmaceuticals Inc (NASDAQ:INO) announced that PharmaVoice, one of the leading industry publications in the life sciences industry, has selected Dr. Niranjan Sardesai as …
In a research report released today, Maxim analyst Jason McCarthy reiterated a Buy rating on shares of Inovio Pharmaceuticals Inc (NASDAQ:INO) and raised the price …
Inovio Pharmaceuticals Inc (NASDAQ:INO) announced that the first patient has been dosed in a phase I trial to evaluate safety and tolerability of PENNVAX®-GP, …
Inovio Pharmaceuticals Inc (NASDAQ:INO) announced its DNA vaccine targeting the virulent Middle East Respiratory Syndrome (MERS) induced 100% protection from a live virus challenge …
Earlier today, Brean Capital’s healthcare analyst Jonathan Aschoff weighed in with research reports on the DNA product development company Inovio Pharmaceuticals Inc (NASDAQ:INO), Biopharmaceutical company Repros Therapeutics Inc (NASDAQ:RPRX), …
Inovio Pharmaceuticals Inc (NASDAQ:INO) shares popped 25.12% to $8.
